FHIR Release 3 (STU)

This page is part of the FHIR Specification (v3.0.2: STU 3). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3 R2

4.2.13.252 HL7 Version 2 Table 0252

Vocabulary Work Group Maturity Level: N/AExternalUse Context: Any

This is a table defined as part of HL7 v2 . Related FHIR content: v2 Causality Observations.

Summary

Name:v2 Causality Observations
Definition:FHIR Value set/code system definition for HL7 v2 table 0252 ( Causality Observations)
Code System URL:http://hl7.org/fhir/v2/0252
Value Set URL:http://hl7.org/fhir/ValueSet/v2-0252
OID:??
CodeSystem ResourceXML / JSON
ValueSet ResourceXML / JSON

This value set is used in the following places:

4.2.13.252.1 Code System Content

Causality Observations

CodeDescriptionNederlands (Dutch)CommentVersion
AW Abatement of event after product withdrawnVermindering gebeurtenis na terugtrekken productadded v2.3
BE Event recurred after product reintroducedGebeurtenis trad opnieuw op na herintroductie productadded v2.3
DR Dose response observedDosis reactie geobserveerdadded v2.3
EX Alternative explanations for the event availableAlternatieve verklaringen voor gebeurtenis beschikbaaradded v2.3
IN Event occurred after product introducedGebeurtenis trad op na introductie productadded v2.3
LI Literature reports association of product with eventLiteratuur vermeldt koppeling van product met gebeurtenisadded v2.3
OE Occurrence of event was confirmed by objective evidenceOptreden van gebeurtenis is bevestigd door objectief bewijsadded v2.3
OT OtherAndersadded v2.3
PL Effect observed when patient receives placeboEffect geobserveerd wanneer patiënt placebo krijgtadded v2.3
SE Similar events in past for this patientVergelijkbare gebeurtenissen in verleden voor deze patiëntadded v2.3
TC Toxic levels of product documented in blood or body fluidsToxische niveaus van product gedocumenteerd in bloed of lichaamssappenadded v2.3